However, despite the anti-tumor efficacy of TLR 7/8a, the clinical applicability of TLR7/8a in cancer immunotherapy is currently limited to skin cancers, including metastatic cancers that present on the skin, due to severe systemic toxicity upon distribution [20]. This evidence concerns the gene TLR7 and neoplasm.